Molecular predictors of locoregional recurrence in breast cancer: Ready for prime time?

Journal of Clinical Oncology

Volumn 28, Issue 10, 2010, Pages 1627-1629

  Haffty, Bruce G ^a   Buchholz, Thomas A ^b  

^a ROBERT WOOD JOHNSON MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKERATIN 5; CYTOKERATIN 6; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; KI 67 ANTIGEN; PROGESTERONE RECEPTOR; TRASTUZUMAB;

BREAST CANCER; CANCER GRADING; CANCER RECURRENCE; CANCER SIZE; EDITORIAL; GENE EXPRESSION PROFILING; HUMAN; IMMUNOHISTOCHEMISTRY; LYMPH NODE METASTASIS; MEDICAL DECISION MAKING; PATIENT CODING; PREDICTOR VARIABLE; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; RISK ASSESSMENT; RISK FACTOR; SCORING SYSTEM; BREAST TUMOR; CLINICAL TRIAL; FEMALE; GENETICS; METASTASIS; NOTE; PATHOLOGY; TUMOR RECURRENCE;

BREAST NEOPLASMS; CLINICAL TRIALS AS TOPIC; FEMALE; GENE EXPRESSION PROFILING; HUMANS; NEOPLASM METASTASIS; NEOPLASM RECURRENCE, LOCAL; RISK ASSESSMENT;

EID: 77950481518     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2009.27.1080     Document Type: Editorial

References (22)

1. Perou CM, Sorlie T, Eisen MB, et al: Molecular portraits of human breast tumours. Nature 406:747-752, 2000
2. Sorlie T, Perou CM, Tibshirani R, et al: Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci U S A 98:10869-10874, 2001 (Pubitemid 32878711)
3. Fasano J, Muggia F: Breast cancer arising in a BRCA-mutated background: Therapeutic implications from an animal model and drug development. Ann Oncol 20:609-614, 2009
4. Paik S, Shak S, Tang G, et al: A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med 351:2817-2826, 2004 (Pubitemid 40051905)
5. Cardoso F, Piccart-Gebhart M, Van't Veer L, et al: The MINDACT trial: The first prospective clinical validation of a genomic tool. Mol Oncol 1:246-251, 2007 (Pubitemid 350181650)
6. Parker JS, Mullins M, Cheang MC, et al: Supervised risk predictor of breast cancer based on intrinsic subtypes. J Clin Oncol 27:1160-1167, 2009
7. Cheng SH, Horng CF, West M, et al: Genomic prediction of locoregional recurrence after mastectomy in breast cancer. J Clin Oncol 24:4594-4602, 2006 (Pubitemid 46630957)
8. Nuyten DS, Kreike B, Hart AA, et al: Predicting a local recurrence after breast-conserving therapy by gene expression profiling. Breast Cancer Res 8:R62, 2006
9. Haffty BG: Molecular and genetic markers in the local-regional management of breast cancer. Semin Radiat Oncol 12:329-340, 2002
10. Haffty BG, Glazer PM: Molecular markers in clinical radiation oncology. Oncogene 22:5915-5925, 2003 (Pubitemid 37176712)
11. Voduc KD, Cheang MCU, Tyldesley S, et al: Breast cancer subtypes and the risk of local and regional relapse. J Clin Oncol 28:1684-1691, 2010
12. Mamounas EP, Tang G, Fisher B, et al: Association between the 21-gene recurrence score assay and risk of locoregional recurrence in node-negative, estrogen receptor - positive breast cancer: Results from NSABP B-14 and NSABP B-20. J Clin Oncol 28:1677-1683, 2010
13. Freedman GM, Anderson PR, Li T, et al: Locoregional recurrence of triple-negative breast cancer after breast-conserving surgery and radiation. Cancer 115:946-951, 2009
14. Haffty BG, Brown F, Carter D, et al: Evaluation of HER-2 neu oncoprotein expression as a prognostic indicator of local recurrence in conservatively treated breast cancer: A case-control study. Int J Radiat Oncol Biol Phys 35:751-757, 1996 (Pubitemid 26251130)
15. Nguyen PL, Taghian AG, Katz MS, et al: Breast cancer subtype approximated by estrogen receptor, progesterone receptor, and HER-2 is associated with local and distant recurrence after breast-conserving therapy. J Clin Oncol 26:2373-2378, 2008
16. Pietras RJ, Poen JC, Gallardo D, et al: Monoclonal antibody to HER-2/neureceptor modulates repair of radiation-induced DNA damage and enhances radiosensitivity of human breast cancer cells overexpressing this oncogene. Cancer Res 59:1347-1355, 1999 (Pubitemid 29136268)
17. Romond EH, Perez EA, Bryant J, et al: Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 353:1673-1684, 2005 (Pubitemid 41464706)
18. Boughey JC, Gonzalez RJ, Bonner E, et al: Current treatment and clinical trial developments for ductal carcinoma in situ of the breast. Oncologist 12:1276-1287, 2007 (Pubitemid 350232601)
19. Haffty BG, Yang Q, Reiss M, et al: Locoregional relapse and distant metastasis in conservatively managed triple negative early-stage breast cancer. J Clin Oncol 24:5652-5657, 2006 (Pubitemid 46631305)
20. Millar EK, Graham PH, O'Toole SA, et al: Prediction of local recurrence, distant metastases, and death after breast-conserving therapy in early-stage invasive breast cancer using a five-biomarker panel. J Clin Oncol 27:4701-4708, 2009
21. Kyndi M, Overgaard M, Nielsen HM, et al: High local recurrence risk is not associated with large survival reduction after postmastectomy radiotherapy in high-risk breast cancer: A subgroup analysis of DBCG 82 b&c. Radiother Oncol 90:74-79, 2009
22. Kyndi M, Sorensen FB, Knudsen H, et al: Tissue microarrays compared with whole sections and biochemical analyses. A subgroup analysis of DBCG 82 b&c. Acta Oncol 47:591-599, 2008